Non-small Cell Lung Cancer
Conditions
Brief summary
This study intends to design a retrospective and prospective, cohort study to explore the association between genetic polymorphism of GSTP1 A313G rs1695 or others and adverse effects of platinum drugs, aiming to explore the risk factors of myelosuppression caused by platinum drugs, and provide data support for optimizing anti-tumor chemotherapy regimen, improve medication safety and improve the compliance of chemotherapy in patients.
Detailed description
Patients with pulmonary malignant tumors receiving platinum-containing chemotherapy regimen were included in the retrospective and prospective bidirectional cohort study to collect the basic information of the subjects, including gender, age, smoking history, primary site, basic liver and kidney function, chemotherapy regimen, etc. The polymorphisms of glutathione S transferase (GSTP1 A313G) were detected by Sanger dideoxy termination sequencing. To study the risk factors related to myelosuppression during chemotherapy, and to preliminarily explore the characteristics of myelosuppression caused by combination chemotherapy with platinum.
Interventions
GENETICGSTP1 A313G （AA）
Patients with pulmonary malignant tumors receiving platinum-containing chemotherapy regimen were included in the retrospective and prospective bidirectional cohort study to collect the basic information of the subjects, including gender, age, smoking history, primary site, basic liver and kidney function, chemotherapy regimen, etc. The polymorphisms of glutathione S transferase (GSTP1 A313G) were detected by Sanger dideoxy termination sequencing. The wild type (AA) and mutant type (AG/GG) were divided into two groups.
Sponsors
LI YAN
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Patients with non-small cell lung cancer with clear imaging or pathological evidence 2. Using a chemotherapy regimen containing platinum 3. Conducted blood routine and biochemical tests 4. Signed informed consent
Exclusion criteria
1. Blood routine and other relevant tests were not performed 2. Suffering from primary bone marrow system disease 3. Other reasons for not meeting the experimental requirements
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of myelosuppression (≤150 days) | The platinum-based regimen was followed by 4 to 6 cycles of chemotherapy (each cycle is 28 days), 4 visits per treatment cycle, and day0, day1, day2-5, day6-21 after chemotherapy were recorded | Myelosuppression was judged according to WHO grading criteria |
Contacts
Primary ContactYI QiaoYan, master
Outcome results
None listed